Public Notice: Announcement of the Fourth Batch of the Shanghai Biopharmaceutical "New and Excellent Medical Products Directory"

Shanghai, China – The Shanghai Municipal Science and Technology Commission has officially announced the public display of the "Shanghai Biopharmaceutical New and Excellent Medical Products Directory" (Fourth Batch). This initiative is in accordance with the guidelines set forth in the document titled "Several Opinions on Supporting the Innovative Development of the Biopharmaceutical Industry" , aimed at promoting innovation and development within the biopharmaceutical sector.

The public notice is open for review from November 15, 2024, to November 21, 2024. During this period, stakeholders and interested parties are encouraged to examine the directory and submit any objections or comments in writing. Individuals must include their name and contact information, while organizations should provide their official seal along with a contact person’s details. The commission assures confidentiality for all respondents.

 Key Details of the Public Notice

- Public Review Period: November 15 - November 21, 2024

- Submission of Objections: Written objections should be sent to the Shanghai Municipal Science and Technology Commission.

- Confidentiality Assured: The commission will keep all respondent information confidential; however, anonymous complaints without clear evidence will not be accepted.

 Submission Information

Materials should be sent to:

Shanghai Municipal Science and Technology Commission  

Biopharmaceutical Division  

200 Renmin Avenue, Shanghai, 200003, China  

 Contact Information

For inquiries or further information, please contact:

- Landline: 8008205114  

- Mobile: 4008205114  

This public notice reflects Shanghai's commitment to fostering innovation in biopharmaceuticals and ensuring that new medical products meet high standards of quality and efficacy.

 About NCC

As a prominent player in the biopharmaceutical industry, NCC is dedicated to advancing healthcare through innovative solutions. Our commitment to quality is demonstrated by our adherence to international standards and certifications. We focus on developing cutting-edge medical devices and pharmaceuticals that enhance patient care and improve health outcomes.

At NCC, we understand the importance of regulatory compliance and actively engage with initiatives like the Shanghai Biopharmaceutical New Product Directory to ensure our products meet stringent safety and efficacy standards. Our team is committed to continuous improvement and innovation, striving to contribute positively to the healthcare landscape.

For more information about NCC's products or to discuss potential collaborations in the biopharmaceutical sector, please reach out to us directly. Together, we can drive advancements in healthcare and improve lives through innovative solutions.